By Chris Wack

Quoin Pharmaceuticals shares doubled to $6.70 in premarket trading after the company said it received clearance from the U.S. Food and Drug Administration to recruit teen subjects aged 14 years and older into its two ongoing clinical trials for QRX003, which is being developed as a potential treatment for Netherton Syndrome.

The specialty pharmaceutical company said both trials are being conducted under Quoin's open Investigational New Drug Application for QRX003.

Quoin said this FDA clearance marks the first time that non-adult Netherton subjects will be tested in clinical studies conducted under an open-IND. Teens who are currently receiving off-label systemic therapy will be eligible to participate in the open-label study, while those who are not receiving such therapy may be recruited into the placebo controlled blinded study.

Write to Chris Wack at

(END) Dow Jones Newswires

03-04-24 0836ET